Nutriband Inc. (OTCQB:NTRB)

Get Top Rated Stock Alerts Active Traders Depend On

Sign Up Today For FREE News Driven Alerts

NUTRIBAND INC. SIGNS ACQUISITION AGREEMENT OF CARMEL BIOSCIENCES AND FDA APPROVED PREXXARTAN™

Orlando, Fla. – Sept 26, 2018 – Nutriband Inc. (OTCQB: NTRB), is pleased to announce it has signed the definitive acquisition agreement to acquire Carmel Biosciences, Inc.  The acquisition is expected to be valued at approximately $2,700,000 and will be paid in company stock in the amount of 350,000 restricted common shares.

 

According to the agreement, Nutriband will acquire the NDA and ownership rights to FDA approved Prexxartan™, the ownership and rights to develop and market Carmel’s pipeline including CAR-509, CAR-510, CAR-511 and CAR-512 currently in Pre IND phase plus rights to Carmel’s clinically tested nutraceutical line.  This includes MET-191, a nutritional supplement which has demonstrated benefit of lipid management, appetite control, and weight management, while improving factors that contribute to the metabolic syndrome.

 

Carmel Biosciences is a pharmaceutical company that addresses critical needs in new drug and liquid reformulation for cardiovascular and metabolic therapies. The Carmel Biosciences team combines a deep understanding of lipid biochemistry and clinical expertise in the cardiovascular and metabolic space.

 

In December 2017 Carmel Biosciences received FDA approval on its first drug PREXXARTAN, the first and Only approved oral liquid dosage form of the angiotensin receptor blocker (ARB) valsartan in the United States.

Oral liquid dosage medications boast a number of benefits such as being better for patients with discomfort swallowing pills, they can often boast faster absorption and flexibility of dosage.

 

PREXXARTAN™ (valsartan oral solution) is indicated for treatment of hypertension in adults and children six years and older. PREXXARTAN™ is also indicated for use as therapy for the treatment of heart failure (NYHA class II-IV). Additionally, PREXXARTAN™ has also been indicated for stable left ventricular failure or left ventricular dysfunction after myocardial infarction.

 

In 2010, valsartan (trade name Diovan) achieved annual sales of $2.052 billion in the United States and $6.053 billion worldwide. The patents for valsartan and valsartan/hydrochlorothiazide expired in September 2012 (Philip Moeller (April 29, 2011). “Blockbuster Drugs That Will Go Generic Soon”. U.S.News & World Report.)

 

Pediatric Hypertension rates are a growing problem in the US with a presence in 2-5% of school-age children.

 

About Nutriband Inc.

 

Nutriband is a results driven, health and pharmaceutical company based in Orlando Florida.  Nutriband’s focus in on the development of novel and unique pharmaceutical and health products to improve treatments for patients, improve patient comfort and safety and more.

Currently all Nutriband products are based around the science of transdermal /topical technologies.

www.nutriband.com – Corporate

www.4Ptherapeutics.com – Clinical Development and prescription pipeline

 

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words “believes”, “anticipates”, “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve both known and unknown risks and uncertainties.  Our actual results may differ materially from those anticipated in our forward-looking statements as a result of a number of factors, including our ability to create, sustain, manage or forecast our growth; our ability to attract and retain key personnel; changes in our business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions.  Except as required by applicable law, we undertake no obligation to revise or update any of our forward-looking statements in order to reflect any event or circumstance that may arise after the date hereof.

 

For more information, contact:

Gareth Sheridan

CEO

Nutriband Inc.

407 880-6810

info@nutriband.com

www.nutriband.com

 

Paul Kuntz

RedChip Companies

407-644-4256, ext. 105

paul@redchip.com

 

SOURCE:  Nutriband Inc.

Nutriband Inc. (OTCQB: NTRB) to Host Investor Webinar to Discuss Acquisition of 4P Therapeutics Inc. & Other Important Recent Developments

ORLANDO, Fla., Aug. 23, 2018 /PRNewswire/ — Nutriband Inc. (OTCQB: NTRB), a pharmaceutical company developing and commercializing a portfolio of prescription pharmaceuticals, OTC’s and consumer products based around the science of transdermal/topical technologies, announced today that Gareth Sheridan, CEO, will host an audio and video webinar, slide presentation and live Q & A session for investors today (Thursday, Aug. 23, 2018) at 4:05 p.m. Eastern.

 

Mr. Sheridan will discuss various key events for Nutriband, among them the acquisition in April 2018 of 4P Therapeutics Inc., a company focusing on transdermal products for currently injected compounds, including proteins, peptides, macromolecules and biologics, and the transformation of 4P Therapeutics into the Pharmaceutical and Development arm of Nutriband. Mr. Sheridan will also talk about Nutriband’s recent appointments to its Advisory Board, among them Sean Gallagher, a former candidate for the presidency of Ireland, who now serves as president of Nutriband.

 

To view the webinar, please visit https://www.redchip.com/events

 

About Nutriband Inc.
Nutriband is a health and pharmaceutical company based in Orlando, Florida. With the acquisition of 4P, Nutriband now has a pipeline of potential transdermal products in various stages of development. All Nutriband products are based around the science of transdermal/topical technologies. Nutriband’s website is www.nutriband.com.

 

About Our Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. Our actual results may differ materially from those anticipated in our forward-looking statements as a result of a number of factors, including our ability to develop and market new products; our ability to complete the necessary testing in order to obtain regulatory approval; the safety and efficacy of any products we develop, our ability to obtain necessary financial to complete the regulatory process and market any products that we develop, our ability to create, sustain, manage or forecast our growth; our ability to attract and retain key personnel; changes in our business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions. Except as required by applicable law, we undertake no obligation to revise or update any of our forward-looking statements in order to reflect any event or circumstance that may arise after the date hereof. Information on our website or any other website does not constitute a part of this press release.

 

For more information, contact:

Gareth Sheridan
CEO
Nutriband Inc.
(407) 880-6810
200592@email4pr.com
www.nutriband.com

Victor Roberts
RedChip Companies
(407) 571-0909
200592@email4pr.com

 

SOURCE Nutriband Inc.

Nutriband Inc. Announces the Appointment of Larry Dillaha, MD as Chief Medical Officer and to Advisory Board

ORLANDO, Fla., Aug. 2, 2018 /PRNewswire/ — Nutriband Inc. (OTCQB: NTRB) announced the appointment of Larry Dillaha, MD as chief medical officer and as a member of its Pharmaceutical Advisory Board.

 

Dr. Dillaha brings nearly 20 years of pharmaceutical industry experience to Nutriband. Prior to joining Nutriband, he was chief executive officer of Repros Therapeutics from February 2017 to February 2018. Prior to joining Repros, Dr. Dillaha was the chief executive officer of CavtheRx, an inception stage biotechnology company, from June 2016 to February 2017, and chief operating officer and chief medical officer of New Haven Pharmaceuticals, a specialty pharmaceutical company. He also served as chief medical officer of Insys Therapeutics, Sciele Pharma and as Medical Director of Sanofi-Sythelabo. Dr. Dillaha received an M.D. degree from the University of Tennessee, Memphis.

 

Garesh Sheridan, Nutriband’s chief executive officer, said, “Dr. Dillaha’s extensive experience includes substantial work in the therapeutic area of pain management, adding to the significant depth of the Nutriband scientific team as we work to develop and commercialize critical ADF transdermal products to this important area of pain therapy.”

 

Nutriband Inc.

Nutriband is a results driven, health and pharmaceutical company based in Orlando, Florida. With the acquisition of 4P, Nutriband now has a pipeline of potential transdermal products in various stages of development. All Nutriband products are based around the science of transdermal/topical technologies. Nutriband’s website is www.nutriband.com.

 

About Our Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. Our actual results may differ materially from those anticipated in our forward-looking statements as a result of a number of factors, including our ability to develop and market new products; our ability to complete the necessary testing in order to obtain regulatory approval; the safety and efficacy of any products we develop, our ability to obtain necessary financial to complete the regulatory process and market any products that we develop, our ability to create, sustain, manage or forecast our growth; our ability to attract and retain key personnel; changes in our business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions. Except as required by applicable law, we undertake no obligation to revise or update any of our forward-looking statements in order to reflect any event or circumstance that may arise after the date hereof. Information on our website or any other website does not constitute a part of this press release.

 

For more information, contact:

Gareth Sheridan

CEO

Nutriband Inc.

407 880-6810

199538@email4pr.com

www.nutriband.com

 

SOURCE Nutriband Inc.

About Nutriband Inc.

Good health is important to all of us, and finding solutions and maintaining technological advances in the area of health care is vital to achieving this.

Nutriband products are on the cutting edge of scientific research to meet the needs of our customers through a unique and simple way; A scientifically formulated dermal patch!

 

Our products are designed on the principle that molecular combinations can be absorbed not only orally but also, through the skin.

 

Transdermal (taking through the skin) technology is not only becoming more and more mainstream in the medicine industry because of its many benefits, it is also the way forward for the Nutriceutical industry.

 

Because of the method of intake, all Nutriband products contain nothing but the bare essential ingredients as there are no need for binders, fillers or unwanted animal by-products such as gelatine.

 

Nutriband Life Sciences is the pharmaceutical division of Nutriband Inc. focused on the development, research and marketing of innovative drug delivery systems.

 

We consistently evaluate our operations and progressions and on listening to the views of all of the people involved in health care decisions such as the FDA and Medical Journals. and our R&D partner’s.

 

Through working in partnership with everyone from Research partners to Manufacturers our goal is to ensure that people everywhere will have access to innovative treatments, technological advances and quality health care.

 

Our Mission

  • To be the leader in Global Transdermal Research and Drug Development
  • To provide alternative treatments using TD technology
  • To better the lives of patients

 

Imagine a world with improved patient compliance, a steady drug delivery state, less frequent dosing, minimal adverse effects, less invasive treatments and problems with gastrointestinal absorption issues are avoided by eliminating the first pass metabolism.

 

Transdermal Drug Delivery Systems

— A Simple, Convenient Way to Get the Remedy You Need —

  • While tablets and injections have been the traditional way to take remedies and medications, new options are becoming increasingly popular.
  • One highly successful alternative delivery method is the transdermal or “through the skin” patch.
  • Patches can offer several benefits, including more consistent symptom control, enhanced convenience, increased tolerability and the potential for fewer side effects.

 

Transdermal Delivery System Advantages:

  • Enhancing bioavailability through bypassing first pass metabolism
  • Minimizing pharmaco-kinetic peaks and troughs
  • Improving tolerability and dosing
  • Increasing patient compliance
  • Continuous delivery

 

Factors that can affect bioavailability: the size and type of pill/capsule, the type of inert ingredients included in the preparation, and the crystalline properties and rates of dissolution of the drug itself.

 

While most prescription, over-the-counter and dietary supplement pills, capsules, or powder formulas may be good, they simply cannot get most of their formula nutrients into your bloodstream, which is where they must go to deliver the benefits and results you want.

 

With today’s advanced time-release transdermal patches, virtually 100% of the formula’s dosages levels are delivered directly into your bloodstream, with no degrading stops along the way (stomach Acids & liver). Better yet, with time-release patches, a person’s system can metabolize the formula nutrients more efficiently.

 

SOURCE:  https://nutriband.com/

Disclaimer

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty sixe hundred dollars for Nutriband Inc. current news coverage by the company.  FNMG HOLDS NO SHARES OF Nutriband Inc.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Sign Up & Get FREE News Alerts From FNM Today!